For non-prescribed supplements, discuss your results with your GP, who may recommend reducing or temporarily stopping supplementation and retesting after 2-3 months
If you want to reduce inflammation: It may sound boring, but its crucial: get plenty of sleep and exercise
When tesamorelin is the more appropriate choice Tesamorelin is typically the preferred agent when: Visceral adipose tissue is the primary treatment target, particularly with associated metabolic comorbidities A clinician is working within a framework that prioritises FDA-approved agents The patient has HIV-associated lipodystrophy, the only approved indication A robust evidence base is required for clinical decision-making For general somatopause-related concerns gradual changes in body composition, sleep quality, and recovery the CJC-1295/ipamorelin combination remains more commonly used, primarily because of its flexible dosing profile and the preserved pulsatile GH release pattern
For the full profile, see Thyroid Premium Platinum
*Oral Diseases*, 22(6), 463-493
Versterk je graag ons team